FUNDAMENTALS |
MarketCap: |
71 435 mill
|
EPS: |
22.38
|
P/E: |
24.29
|
Earnings Date: |
Jul 19, 2024 |
SharesOutstanding: |
131.41 mill
|
Avg Daily Volume: |
0.667 mill
|
RATING
2024-05-08 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
1.57x
|
Company: PE 24.29 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
0.94x
|
Company: PE 24.29 | industry: PE 25.81
|
DISCOUNTED CASH FLOW VALUE |
$893.82
(64.42%)
$350.21
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 535.04 - 552.18
( +/- 1.58%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-15 | Tyler Brian S. | Buy | 3 473 | Common Stock |
2024-03-15 | Tyler Brian S. | Sell | 3 473 | Common Stock |
2024-03-15 | Tyler Brian S. | Sell | 3 473 | Employee Stock Option (Right-to-buy) |
2024-03-01 | Rutledge Napoleon B Jr | Buy | 613 | Common Stock |
2024-03-01 | Rutledge Napoleon B Jr | Sell | 183 | Common Stock |
INSIDER POWER |
-47.88
|
Last
99 transactions |
Buy:
81 873 | Sell:
255 959 |
Forecast:
16:00 - $543.61
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $543.61
Forecast 2: 16:00 - $543.61
Forecast 3: 16:00 - $543.61
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$543.61 (-0.39% )
|
Volume |
1.377 mill
|
Avg. Vol. |
0.667 mill
|
% of Avg. Vol |
206.32 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For MCK
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.